7Suzanne L. Topalian,F. Stephen Hodi,Julie R. Brahmer.Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. New England Journal of Homeopathy . 2012 被引量：2
8Tetsuya Mitsudomi,Satoshi Morita,Yasushi Yatabe,Shunichi Negoro,Isamu Okamoto,Junji Tsurutani,Takashi Seto,Miyako Satouchi,Hirohito Tada,Tomonori Hirashima,Kazuhiro Asami,Nobuyuki Katakami,Minoru Takada,Hiroshige Yoshioka,Kazuhiko Shibata,Shinzoh Kudoh,Eiji Shimizu,Hiroshi Saito,Shinichi Toyooka,Kazuhiko Nakagawa,Masahiro Fukuoka.Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial[J]. Lancet Oncology . 2010 (2) 被引量：8
9Adrian G. Sacher,Pasi A. J?nne,Geoffrey R. Oxnard.Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non‐small cell lung cancer[J]. Cancer . 2014 (15) 被引量：1
10Ingrid Torjesen.Genomes of 100?000 people will be sequenced to create an open access research resource[J]. BMJ . 2013 (nov0) 被引量：1
